Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Allergy

Therapeutic area intelligence for Allergy with 15 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 15
Catalysts: 0
Companies: 4

Companies

allergy therapeutics companies →

Annora Pharma →

Macleods Pharmaceuticals →

Unique Pharmaceutical Laboratories →

Assets

Levocetirizine →

Remibrutinib →

Recent signals(15)

StrategyAugust 5, 2026

FDA Grants Approval for Fexofenadine Hydrochloride ANDA220413 by Dr. Reddy's

The FDA has granted approval for Dr. Reddy's Abbreviated New Drug Application for Fexofenadine Hydrochloride.

ClinicalJuly 30, 2026

Remibrutinib Shows Promise in Peanut Allergy Trial

A study is underway to evaluate remibrutinib's safety and efficacy in adults with peanut allergies, focusing on dose tolerance.

RegulatoryJuly 25, 2026

FDA Approves Supplemental Application for Children's Allegra Hives

The FDA has approved a supplemental application for Children's Allegra Hives, containing fexofenadine hydrochloride.

RegulatoryJuly 23, 2026

FDA Grants AP Status for Azelastine Hydrochloride and Fluticasone Propionate

The FDA has granted Abbreviated Approval (AP) status for ANDA208111, a combination of Azelastine Hydrochloride and Fluticasone Propionate.

RegulatoryJuly 21, 2026

Unique Pharmaceutical Laboratories Recalls Cetirizine Hydrochloride Due to Ranitidine Contamination

Unique Pharmaceutical Laboratories is recalling four lots of Cetirizine Hydrochloride Tablets due to cross contamination with Ranitidine.

ClinicalJuly 17, 2026

Study on Maternal Diet Impact on Infant Peanut and Egg Allergy Development

The study investigates how maternal consumption or avoidance of peanuts and eggs during pregnancy affects infant allergy development.

RegulatoryJuly 16, 2026

FDA Approves Supplemental Application for Children's Zyrtec Hives

The FDA has approved a supplemental application for Children's Zyrtec Hives, containing cetirizine hydrochloride.

StrategyJuly 16, 2026

FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564

The FDA has granted Abbreviated Approval (AP) status for ANDA205564, a generic formulation of Levocetirizine Dihydrochloride by Macleods Pharmaceuticals.

RegulatoryJuly 12, 2026

FDA Accepts Supplement for RYALTRIS by Glenmark

The FDA has accepted a supplemental application for RYALTRIS, which contains mometasone furoate and olopatadine hydrochloride.

StrategyJuly 9, 2026

Apotex submits ANDA for Azelastine Hydrochloride and Fluticasone Propionate

Apotex has submitted an Abbreviated New Drug Application (ANDA) for a combination product of Azelastine Hydrochloride and Fluticasone Propionate.

RegulatoryJuly 3, 2026

FDA Reports Increase in Accidental Overdoses of Apoquel Chewable in Dogs

The FDA has noted a rise in reports of accidental overdoses of Apoquel Chewable in dogs.

RegulatoryJune 30, 2026

FDA Approves Supplemental Application for Children's Allegra Hives

The FDA has approved a supplemental application for Children's Allegra Hives, containing fexofenadine hydrochloride.

CompetitiveJune 25, 2026

Study on Epinephrine Auto-injector Needle Depth for Anaphylaxis Treatment

The study evaluates the depth of epinephrine delivery using different auto-injector devices for anaphylaxis treatment.

StrategyJune 24, 2026

FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470

The FDA has granted approval for ANDA219470, a generic version of Diphenhydramine Hydrochloride by Annora Pharma.

RegulatoryJune 18, 2026

FDA Approves Supplemental Application for Zyrtec Hives by Kenvue Brands

The FDA has approved a supplemental application for Zyrtec Hives, containing cetirizine hydrochloride.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.